Health

Benign Prostatic Hyperplasia Surgical Devices Market Set Explosive Growth to 2026

Benign prostatic hyperplasia (BPH) is a medical condition, which is characterized by non-cancerous enlargement of prostate and it generally affects men aged more than 50 years. According to the study published in The Lancet in 2015, more than 100 million people were suffering from benign prostatic hyperplasia (BPH) globally. Drugs such as Alpha- blockers and 5α-Reductase inhibitors (5ARIs), surgery such as transurethral resection of the prostate (TURP), and minimally invasive surgeries such as implants, radiofrequency ablation, and lasers are the primary treatment options available for the disease. As surgery and minimally invasive therapy offers permanent solution, the benign prostatic surgical devices market is expected to grow significantly during the forecast period.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/1199

Market Dynamics

Increasing demand for minimally invasive therapy such as implants, prostatic stents and laser therapy are expected to be primary driving force for this market. Although implant has entered very late in benign prostatic hyperplasia market, its demand is increasing. NeoTract, Inc. received the approval for first implant for benign prostatic hyperplasia in 2010 and 2013 in Europe and U.S. respectively. This huge transaction value underlines the market opportunity for such products in developed economies such as the U.S. and European economies in short-term period and globally in long-term period. Other novel treatment options such as prostatic artery embolization (PAE) has also gained traction in recent years and its application for benign prostatic hyperplasia treatment is expected to get streamlined in near future. The introduction of novel treatments options such as PAE is expected to lead to further growth in the market. Moreover, increasing aging population, which is more prone to the disease is expected to support the growth of this market. According to Population Reference Bureau, the number of American people aged 65 years and above is expected to more than double from 46 million in 2014 to 98 million by 2060.

Increasing demand for minimally invasive therapies is expected to boost growth of the benign prostatic hyperplasia surgical devices market

Minimally invasive surgeries have gained traction in the recent past, owing to various advantages such as significant reduction in postoperative pain, decreased recovery time, reduced hospital stays, lesser surgical scars, laparoscopic incisions being safer than open incisions, equivalent or better safety, and efficacy in abdominal and general surgeries as compared to open surgeries, and these surgeries may be less expensive than open surgeries. Moreover, these therapies offer one-time permanent solution rather than long-time dependent on medications. Currently, more than 60% and 20% of patients suffering from benign prostatic hyperplasia is on drugs and under observation. The minimally invasive therapies are focusing on these groups particularly and have also witnessed some success in attracting such customers.

Increasing geriatric population is expected to drive the growth of benign prostatic hyperplasia surgical devices market

Benign prostatic hyperplasia is the most common prostate problem in men aged 50 years and above and the occurrence of the same tends to increase with age. According to the U.S. Census Bureau, 2015, among 7.3 billion people worldwide, an estimated 617.1 million people were aged 65 years and older and the number of geriatric population is expected to increase above 60% by year 2030 indicating the potential population base associated with lower urinary tract symptoms (LUTS) resulting due to benign prostatic hyperplasia. According to the Population Reference Bureau, numbers of American aged 65 years and above are expected to reach up to 98 million by 2060, more than double from 2014 and will constitute about one-fourth of the total population. This increasing aging population presents immense market opportunity for companies, specifically start-ups working on novel therapies such as ProVerum Limited, ProArc Medical and Zenflow, and Others.

Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/1199

Some major players operating in the benign prostatic hyperplasia surgical devices market are Olympus Corporation, Boston Scientific Corporation, Medifocus Inc., KARL STORZ SE & Co. KG, NxThera, Inc., ProArc Medical, Lisa Laser Products OHG, and Richard Wolf Gmbh.